Showing results (51-60 of 305) with videos related to

Sort By:
Pageof 31
Cancers|January 26, 2020
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted DrugsCandida Vitale, Maria Chiara Montalbano, Chiara Salvetti, et al.
British Journal of Haematology|May 11, 2012
Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survivalElena Crisà, Cristina Foli, Roberto Passera, et al.
Expert Review of Anticancer Therapy|June 7, 2008
Lenalidomide and its role in the management of multiple myelomaPatrizia Falco, Federica Cavallo, Alessandra Larocca, et al.
Oncology|February 7, 2007
Management of multiple myeloma with bortezomib: experts review the data and debate the issuesMario Dicato, Mario Boccadoro, Jamie Cavenagh, et al.
Current Hematologic Malignancy Reports|April 29, 2010
Treatment of newly diagnosed multiple myelomaAntonio Palumbo, Valeria Magarotto, Alessandra Larocca, et al.
European Journal of Haematology|March 8, 2006
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myelomaAntonio Palumbo, Ilaria Avonto, Benedetto Bruno, et al.
British Journal of Haematology|November 28, 2008
Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromesDario Ferrero, Antonella Darbesio, Valentina Giai, et al.
Clinical Case Reports|March 19, 2020
Extended half-life rFIX in major surgery-How to improve clinical practice: An intraindividual comparisonFederica Valeri, Jacopo Agnelli Giacchello, Cristina Dainese, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2015
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)Pere Gascón, Matti Aapro, Heinz Ludwig, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 22, 2018
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF studyHeinz Ludwig, Pere Gascón, Carsten Bokemeyer, et al.
Pageof 31